The ROE as of September 2024 (TTM) for BioXcel Therapeutics, Inc. (BTAI) is 176.93%

According to BioXcel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 176.93%. This represents a change of 233.99% compared to the average of 52.98% of the last 4 quarters.

BioXcel Therapeutics, Inc. (BTAI) Historical ROE (quarterly & annually)

How has BTAI ROE performed in the past?

The mean historical ROE of BioXcel Therapeutics, Inc. over the last ten years is 105.78%. The current 176.93% ROE has changed 67.27% with respect to the historical average. Over the past ten years (40 quarters), BTAI's ROE was at its highest in in the December 2017 quarter at 257.43%. The ROE was at its lowest in in the June 2023 quarter at -912.60%.

BioXcel Therapeutics, Inc. (BTAI) ROE by Quarter and Year

Discovering the peaks and valleys of BioXcel Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BioXcel Therapeutics, Inc. (BTAI) Average ROE

How has BTAI ROE performed in the past?

The current ROE of BioXcel Therapeutics, Inc. (BTAI) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

BioXcel Therapeutics, Inc. (BTAI) ROE vs. Peers

How is BTAI’s ROE compared to its peers?

BioXcel Therapeutics, Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), less than Exelixis, Inc. (15.80%), greater than TG Therapeutics, Inc. (-38.21%), greater than Viking Therapeutics, Inc. (-15.05%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Elevation Oncology, Inc. (-57.97%), greater than Mereo BioPharma Group plc (-63.39%), greater than Hepion Pharmaceuticals, Inc. (-328.66%),

Build a custom stock screener for BioXcel Therapeutics, Inc. (BTAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioXcel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioXcel Therapeutics, Inc. (BTAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioXcel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.